SEC Form 4 · accession 0001209191-17-047734
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Franc Del Fosse
Officer — General Counsel
Period of report
Jul 31, 2017
Accepted (ET)
Aug 4, 2017 · 4:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Jul 31, 2017 | A | 8,000 | A | — | — | Common Stock | 8,000 | 8,000 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F2Represents shares issuable upon the vesting of restricted stock units ("RSUs") awarded to the Reporting Person on July 31, 2017. The RSUs vest in 2 equal annual installments beginning on July 31, 2018 and will be fully vested on July 31, 2019, in all cases so long as there has been no break in the Reporting Person's continuous service through such date.